Global Chronic Kidney Disease (CKD) Drugs Market Marks Control of North America Owing to Rising Diabetes, Obesity Disorders

The global chronic kidney disease (CKD) drugs market is set to gather a toughening impetus from the intensifying need of novel treatments to better the sufferer’s quality of life alongside the growing number of CKD patients. According to a recent news, biopharmaceutical firm Reata Pharmaceuticals, Inc. operating at clinical stage has received orphan designation by the U.S. Food and Drug Administration (FDA) for bardoxolone methyl used for treating Alport syndrome which could cause CKD. As per the observations of Reata CEO, presently, there are no FDA-approved treatments for the syndrome and this orphan designation is a significant landmark for the company.

Leading market research business, Transparency Market Research (TMR) foresees the global CKD drugs market to earn an approximate US$15.8 bn by the close of 2024 at a 3.60% CAGR during the forecast period 2016–2024. In 2015, the market had reached a US$11.5 bn.

Will North America Maintain Lead Until 2024?

Among the five key regions of the world CKD drugs market, viz. the Middle East and Africa, Latin America, Asia Pacific, and Europe, North America is prophesied to take a leading position, recalling its dominant share of 31.8% in 2015. Heavy adoption of forward-thinking technological offerings and sturdy economic condition could be vital for the growth of the leading region in the coming years. North America is foretold to gain traction on the back of the growing number of diabetes cases and disorders related to obesity.

In view of a wide pool of kidney cancer patients in the region, Europe could secure the second position in the list of leading geographical markets for CKD drugs. The growth in Europe is anticipated to be bolstered by the high application and adoption of superior-quality treatments and telling enlargement of the medical and healthcare sector in chief markets such as Australia, Japan, and China.

Which Drug Class will Attract Attention in Future?

One of the primary parameters to gauge the success of a market is end use. As for the international CKD drugs market, seasoned analysts envisage specialty clinics and hospitals to augur considerably well in the near future. Out of these, hospitals could showcase authority until the concluding forecast year, continuing from its current dominance in the market. By class of drug, the market could be segregated into different segments, amongst which calcium channel blockers had accounted for an impressive share of 18.9% in 2015. Dihydropiridines, phenyl alkyl amines, and benzothiazepines are some of the salient calcium channel blockers engaged around the globe.

The competitive landscape of the worldwide CKD drugs market could demonstrate a consolidated characteristic in the foreseeable future as top players focus on strategic alliances, acquisitions, and mergers to secure a stronghold in the industry. AbbVie Inc., Amgen Inc., Pfizer Inc., and Sanofi S.A. had fetched a hefty collective share in 2015.


Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports